Core Viewpoint - On October 9, Haixiang Pharmaceutical announced a share buyback plan, indicating a strategic move to enhance shareholder value and confidence in the company's future performance [1] Summary by Categories Company Actions - Haixiang Pharmaceutical has repurchased a total of 4,410,000 shares, which represents 0.27% of the company's total share capital [1]

Group 1 - Company HaiXiang Pharmaceutical announced a share buyback of 4.41 million shares, representing 0.27% of its total share capital, with a total transaction amount of approximately 26.09 million RMB [1] - The highest transaction price during the buyback was 6.29 RMB per share, while the lowest was 5.66 RMB per share [1] - As of the report, the market capitalization of HaiXiang Pharmaceutical is 9.5 billion RMB [1] Group 2 - For the first half of 2025, the revenue composition of HaiXiang Pharmaceutical is as follows: 65.89% from the pharmaceutical manufacturing sector, 33.09% from the dye industry, and 1.02% from other sources [1]

Core Viewpoint - Haisheng Pharmaceutical (002099.SZ) has announced a share buyback program, reflecting its commitment to enhancing shareholder value through strategic capital management [1] Summary by Categories Share Buyback Details - As of September 30, 2025, the company has repurchased a total of 4,410,000 shares, which represents 0.27% of its total share capital [1] - The highest transaction price during the buyback was 6.29 CNY per share, while the lowest was 5.66 CNY per share [1] - The total amount spent on the buyback reached 26,090,960.52 CNY, excluding transaction fees [1] Compliance and Strategy - The share repurchase is in accordance with relevant laws and regulations, aligning with the company's established buyback plan [1]

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.66% on October 9, with Nanjing New Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Haichen Pharmaceutical (300584) with a closing price of 63.81, up 13.76% and a trading volume of 155,800 shares, totaling 973 million yuan [1] - Changshan Pharmaceutical (300255) closed at 49.29, up 8.21% with a trading volume of 394,400 shares, totaling 1.916 billion yuan [1] - Conversely, Nanjing New Pharmaceutical (688189) saw a significant drop of 19.96%, closing at 9.10 with a trading volume of 32,300 shares, totaling 29.426 million yuan [2] Capital Flow - The chemical pharmaceutical sector experienced a net outflow of 1.108 billion yuan from institutional investors, while retail investors saw a net inflow of 544 million yuan [2] - The capital flow for specific stocks showed: - Changshan Pharmaceutical had a net inflow of 14.6 million yuan from institutional investors, but a net outflow of 14 million yuan from retail investors [3] - Haichen Pharmaceutical recorded a net inflow of 85.3 million yuan from institutional investors, with retail investors showing a net outflow of 68 million yuan [3]

证券代码：002099 证券简称：海翔药业 公告编号：2025-042 浙江海翔药业股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）于 2025 年 4 月 9 日召开 第七届董事会第十三次会议，审议通过了《关于回购股份方案的议案》，同意公 司使用自有/自筹资金以集中竞价交易方式回购部分公司股票（以下简称"本次 回购"），在未来适宜时机用于股权激励或者员工持股计划。本次回购资金总额 不低于人民币 15,000 万元（含），不超过人民币 30,000 万元（含），回购价格 不超过人民币 7.46 元/股（含）。本次回购的实施期限自董事会审议通过本回购 方案之日起 12 个月内。具体内容详见公司于 2025 年 4 月 10 日在《证券时报》 《证券日报》和巨潮资讯网（www.cninfo.com.cn）上披露的《关于回购股份方 案的公告》（公告编号：2025-005）。 （二）公司以集中竞价交易方式回购股份符合下列要求： 一、回购公司股份的进展情况 截至 2025 年 9 月 ...

Group 1 - The company, Haixiang Pharmaceutical, stated on September 25 that it strictly complies with the relevant laws and regulations of the China Securities Regulatory Commission and the Shenzhen Stock Exchange regarding information disclosure obligations [2] - The company mentioned that investors should pay attention to relevant announcements regarding its employee stock ownership plan and share repurchase matters [2]

（文章来源：证券日报） 证券日报网讯海翔药业9月24日在互动平台回答投资者提问时表示，截至9月19日公司股东人数为26641 户。 ...

Summary of Key Points Core Viewpoint - Haisheng Pharmaceutical has experienced a decline in the number of shareholders and a decrease in stock price, indicating potential challenges in its financial performance and investor sentiment [2]. Group 1: Shareholder and Stock Performance - As of September 20, the number of shareholders for Haisheng Pharmaceutical was 26,641, a decrease of 2,277 from the previous period (September 10), representing a decline of 7.87% [2]. - The latest stock price for Haisheng Pharmaceutical is 5.88 yuan, remaining flat, with a cumulative decline of 8.13% since the concentration of shares began [2]. - The stock has seen 3 days of increases and 6 days of decreases during this period [2]. Group 2: Financing and Margin Data - As of September 23, the margin trading balance for the stock was 866 million yuan, with a financing balance of 865 million yuan [2]. - The financing balance has decreased by 2.8457 million yuan, reflecting a decline of 0.33% since the concentration of shares began [2]. Group 3: Financial Performance - In the first half of the year, Haisheng Pharmaceutical reported total revenue of 925 million yuan, a year-on-year decrease of 10.94% [2]. - The net profit for the same period was 14.0937 million yuan, down 63.01% year-on-year [2]. - The basic earnings per share were 0.0100 yuan, with a weighted average return on equity of 0.27% [2].

证券日报网讯海翔药业（002099）9月11日在互动平台回答投资者提问时表示，截至9月10日公司股东人 数为28918人。 ...

Group 1 - The company, Haixiang Pharmaceutical, reported that as of August 29, the number of shareholders was 29,261 [1]